1 citations
,
February 2025 in “Notulae Scientia Biologicae” Optimized emulgels with Levofloxacin effectively treat eye infections with prolonged drug release and safety.
89 citations
,
November 2014 in “International Journal of Nanomedicine” Using nanostructured lipid carriers to deliver spironolactone could improve treatment for hair loss.
May 2024 in “Reactions weekly”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
54 citations
,
January 1980 in “Dermatology” 17α-estradiol lotion can reduce hair loss but doesn't promote new hair growth.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
December 2024 in “Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi” Both treatments are safe and effective, but anthralin may work better for some patients.
19 citations
,
December 2019 in “Journal of the American Academy of Dermatology” 5 mg/mL of triamcinolone acetonide is most effective for hair regrowth with fewer side effects.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
January 2023 in “JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH” Combining injections with lotion is more effective for hair regrowth in alopecia areata than using the lotion alone.
2 citations
,
March 2022 in “Dermatologic Therapy” Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.
7 citations
,
April 2021 in “Journal of Pharmacy and Pharmaceutical Sciences” Cetirizine 1% helps hair growth in men with no major side effects, but minoxidil 5% works better.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
27 citations
,
January 1986 in “PubMed” 1% minoxidil didn't improve hair growth for severe alopecia areata.
37 citations
,
March 1986 in “Acta Dermato Venereologica” 1% minoxidil didn't improve hair growth in severe alopecia areata.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
81 citations
,
August 2011 in “Journal of The American Academy of Dermatology” Latanoprost 0.1% may effectively treat hair loss.
October 2021 in “Journal of Investigative Dermatology” Edelweiss extract may help prevent hair loss and increase hair density.
8 citations
,
November 2022 in “Cureus” Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
October 2025 in “Scholars Journal of Medical Case Reports” Intralesional corticosteroids effectively treat scalp Discoid Lupus and restore hair.
22 citations
,
March 2019 in “European Journal of Ophthalmology” Preservative-free latanoprost effectively lowers eye pressure with fewer side effects.
October 2025 in “Archives of Dermatological Research” Topical metformin gel is as effective and safe as steroids for treating alopecia areata.
1 citations
,
February 2015 in “Journal of evolution of medical and dental sciences” 0.05% Betamethasone Dipropionate is the most effective topical treatment for alopecia areata.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.